Purpose

The National Cancer Institute is the only referral centre in Malaysia that provides ⁶⁸Ga-DOTA-peptide imaging. The purpose of this study is to determine the impact of ⁶⁸Ga-DOTA-peptide PET/CT on the management of gastrointestinal neuroendocrine tumours (GI-NET).

Materials and Methods

A cross-sectional study was performed to review the impact of ⁶⁸Ga-DOTA-peptide (⁶⁸Ga-DOTATATE or ⁶⁸Ga-DOTATOC) PET/CT on patients with biopsy-proven GI-NET between January 2011 and December 2015. Suspected NET was excluded. Demographic data, tumoral characteristics, change of disease stage, pre-PET intended management and post-PET management were evaluated.

Results

Over a 5-year period, 82 studies of ⁶⁸Ga-DOTA-peptide PET/CT were performed on 44 GI-NET patients. The most common primary site was the rectum (50.0%) followed by the small bowel, stomach and colon. Using WHO 2010 grading, 40.9% of patients had low-grade (G1) tumour, 22.7% intermediate (G2) and 4.5% high (G3). Of ten patients scheduled for pre-operative staging, ⁶⁸Ga-DOTA-peptide PET/CT only led to therapeutic change in three patients. Furthermore, false-negative results of ⁶⁸Ga-DOTA-peptide PET/CT were reported in one patient after surgical confirmation. However, therapeutic changes were seen in 20/36 patients (55.6%) scheduled for post-surgical restaging or assessment of somatostatin analogue (SSA) eligibility. When ⁶⁸Ga-DOTA-peptide PET/CT was used for monitoring disease progress during systemic treatment (sandostatin, chemotherapy, everolimus and PRRT) in metastatic disease, impact on management modification was seen in 19/36 patients (52.8%), of which 84.2% had inter-modality change (switch to everolimus, chemotherapy or PRRT) and 15.8% had intra-modality change (increased SSA dosage).

Conclusions

⁶⁸Ga-DOTA-peptide PET/CT has a significant impact on management decisions in GI-NET patients as it can provide additional information on occult metastasis/equivocal lesions and supply the clinician an opportunity to select patients for targeted therapy.

1. Reubi, J. C., & Waser, B. (2003). Concomitant expression of several peptide receptors in neuroendocrine tumors: Molecular basis for in vivo multireceptor tumour targeting. European Journal of Nuclear Medicine and Molecular Imaging, 30, 781–793.
2. Kulkarni, H. R., & Baum, R. P. (2014). Theranostics with Ga-68 somatostatin receptor PET/CT: Monitoring response to peptide receptor radionuclide therapy. PET Clinics, 9, 91–97.
3. Kulkarni, H. R., & Baum, R. P. (2014). Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT. PET Clinics, 9, 83–90.
4. Deppen, S. A., Liu, E., Blume, J. D., et al. (2016). Safety and efficacy of 68Ga DOTATATE PET/CT for diagnosis, staging, and treatment management of neuroendocrine tumors. Journal of Nuclear Medicine, 57, 708–714.
5. Antunes, P., Ginj, M., Zhang, H., Waser, B., Baum, R. P., Reubi, J. C., et al. (2007). Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? European Journal of Nuclear Medicine and Molecular Imaging, 34, 982–993.
6. Ambrosini, V., et al. (2012). 68Ga-labelled peptides for diagnosis of gastroenteropancreatic NET. European Journal of Nuclear Medicine and Molecular Imaging, 39, S52–S60.
7. Buchmann, I., Henze, M., Engelbrecht, S., Eisenhut, M., Runz, A., Schäfer, M., et al. (2007). Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 34, 1617–1626.
8. Krausz, Y., Freedman, N., Rubinstein, R., Lavie, E., Orevi, M., Tshori, S., et al. (2011). 68Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: Comparison with 111In-DTPA-octreotide (OctreoScan®). Molecular Imaging and Biology, 13, 583–593.
9. Naswa, N., Sharma, P., Kumar, A., Nazar, A. H., Kumar, R., Chumber, S., et al. (2011). Gallium-68-DOTA-NOC PET/CT of patients with gastroenteropancreatic neuroendocrine tumors: A prospective single-center study. American Journal of Roentgenology, 197, 1221–1228.
10. Hofman, M. S., Kong, G., Neels, O. C., Eu, P., Hong, E., & Hicks, R. J. (2012). High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours. Journal of Medical Imaging and Radiation Oncology, 56, 40–47.
11. Ambrosini, V., Campana, D., Bodei, L., et al. (2010). 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. Journal of Nuclear Medicine, 51, 669–673.
12. Herrmann, K., Czernin, J., Wolin, E. M., et al. (2015). Impact of 68Ga-DOTATATE PET/CT on the management of neuroendocrine tumors: The referring physician’s perspective. Journal of Nuclear Medicine, 56, 70–75.
13. Skoura, E., Michopoulou, S., Mohmaduvesh, M., et al. (2016). The impact of 68Ga-DOTATATE PET/CT imaging on management of patients with neuroendocrine tumors: Experience from a National Referral Center in the United Kingdom. Journal of Nuclear Medicine, 57, 34–40.
14. Kratochwil, C., Stefanova, M., Mavriopoulou, E., et al. (2015). SUV of [68Ga]DOTATOC-PET/CT predicts response probability of PRRT in neuroendocrine tumors. Molecular Imaging and Biology, 17, 313–318.
15. Kayani, I., Bomanji, J. B., Groves, A., Conway, G., Gacinovic, S., Win, T., et al. (2008). Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. Cancer, 112(11), 2447–2455.
16. Oh, S., Prasad, V., Lee, D. S., & Baum, R. P. (2011). Effect of peptide receptor radionuclide therapy on somatostatin receptor status and glucose metabolism in neuroendocrine tumors: Intraindividual comparison of Ga-68 DOTANOC PET/CT and F-18 FDG PET/CT. International Journal of Molecular Imaging, 2011.
17. Gabriel, M., Oberaurl, A., Dobrozemskyl, G., et al. (2009). 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy. Journal of Nuclear Medicine, 50, 1427–1434.
18. Garcia-Carbonero, R., et al. (2015). Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): Current perspectives and future trends of an exciting field in development. Cancer Metastasis Reviews, 34, 823–842.